In summary, PDUFA remains a cornerstone of the current FDA drug review method, especially since Congress has shown no interest in rising direct appropriations into the agency. The service fees generated by PDUFA have allowed the FDA to hire additional employees, substantially improve overview times for drugs and biologics, and increase use of essen